Etomoxir (sodium salt)
Etomoxir ((R) - (+) -Etomoxir) sodium salt is an irreversible inhibitor of carnitine palmitoyltransferase 1a (CPT-1a), inhibits fatty acid oxidation (FAO) through CPT-1a and inhibits palmitate β-oxidation in human, rat and guinea pig[1].
Product Specifications
CAS Number
[828934-41-4]
Product Name Alternative
(R) - (+) -Etomoxir (sodium salt)
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis
Type
Reference compound
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Metabolic Disease; Cancer
Assay Protocol
https://www.medchemexpress.com/_R_-__addition__-Etomoxir-sodium-salt.html
Purity
99.62
Solubility
DMSO : 50 mg/mL (ultrasonic) |H2O : 5 mg/mL (ultrasonic)
Smiles
ClC1=CC=C(OCCCCCC[C@@]2(CO2)C(O[Na])=O)C=C1
Molecular Formula
C15H18ClNaO4
Molecular Weight
320.74
Precautions
H302, H315, H319, H335
References & Citations
[1]Roddy S O'Connor, et al. The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations.Sci Rep. 2018 Apr 19;8 (1) :6289.|[2]Fred Y Xu, et al.Etomoxir mediates differential metabolic channeling of fatty acid and glycerol precursors into cardiolipin in H9c2 cells.J Lipid Res. 2003 Feb;44 (2) :415-23.|[3]Jun Li, et al. FFA-ROS-P53-mediated mitochondrial apoptosis contributes to reduction of osteoblastogenesis and bone mass in type 2 diabetes mellitus.Sci Rep. 2015 Jul 31;5:12724.|[4]Joost J F P Luiken, et al. Etomoxir-induced partial carnitine palmitoyltransferase-I (CPT-I) inhibition in vivo does not alter cardiac long-chain fatty acid uptake and oxidation rates.Biochem J. 2009 Apr 15;419 (2) :447-55.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, protect from light, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Citation 01
Am J Physiol Cell Physiol. 2025 Mar 1;328 (3) :C776-C790.|Am J Physiol Gastrointest Liver Physiol. 2025 Jun 1;328 (6) :G663-G676.|Antimicrob Agents Chemother. 2018 Apr 26;62 (5) . pii: e01659-17. |Cancer Lett. 2024 Jun 18:217068.|Cell Death Dis. 2022 Mar 11;13 (3) :229.|Cell Metab. 2022 Nov 1;34 (11) :1843-1859.e11.|Cell Rep. 2019 Apr 2;27 (1) :226-237.e4.|Cell Stem Cell. 2025 Dec 4;32 (12) :1849-1868.e15.|Dev Cell. 2025 Apr 18:S1534-5807 (25) 00206-0.|J Invest Dermatol. 2023 Oct;143 (10) :1993-2006.e10.|Life Sci. 2024 Aug 1:350:122763.|Lipids Health Dis. 2024 Feb 3;23 (1) :37.|Mol Cell. 2020 Oct 1;80 (1) :43-58.e7.|Mol Cell. 2022 Aug 18;82 (16) :3030-3044.e8.|Redox Biol. 2018 Jul;17:180-191.|Research Square Preprint. 2023 Aug 1.|Acta Biomater. 2022 Sep 15:150:83-95.|Acta Pharm Sin B. 2024 Nov 7.|Acta Pharmacol Sin. 2025 May 20.|Adv Sci (Weinh) . 2024 Nov 26:e2411559.|Adv Sci (Weinh) . 2025 Nov 6:e07384.|Aging Cell. 2024 Aug;23 (8) :e14184.|Ann Med. 2025 Dec;57 (1) :2497112.|Arterioscler Thromb Vasc Biol. 2025 Aug 21.|Autophagy. 2025 Jan;21 (1) :80-101.|Biochem Biophys Res Commun. 2017 Feb 5;483 (2) :860-866.|Biochem Biophys Res Commun. 2021 Oct 8:583:135-141.|Biochim Biophys Acta Mol Basis Dis. 2024 Jun 25:167314.|Biochim Biophys Acta Mol Basis Dis. 2025 May 24:167919.|bioRxiv. 2021 Mar 8.|bioRxiv. 2023 Apr 17.|bioRxiv. 2023 Nov 17.|bioRxiv. 2025 April 10.|bioRxiv. 2025 May 15.|Brain. 2024 Aug 28:awae270.|Cancer Cell Int. 2023 May 9;23 (1) :87.|Cancer Cell Int. 2025 May 14;25 (1) :176.|Cancer Cell. 2025 Jun 9;43 (6) :1108-1124.e11.|Cancer Res. 2023 Aug 1;83 (15) :2461-2470.|Cell Biol Int. 2024 Sep;48 (9) :1378-1391.|Cell Death Dis. 2023 Feb 15;14 (2) :125.|Cell Death Dis. 2023 Oct 6;14 (10) :653.|Cell Death Dis. 2025 Apr 14;16 (1) :291.|Cell Death Discov. 2024 May 1;10 (1) :207.|Cell Metab. 2023 Dec 5;35 (12) :2136-2152.e9.|Cell Metab. 2024 May 7;36 (5) :969-983.e10.|Cell Mol Gastroenterol Hepatol. 2025 May 21:101539.|Cell Physiol Biochem. 2018;48 (6) :2318-2336. |Cell Prolif. 2021 Nov;54 (11) :e13134.|Cell Rep Med. 2024 May 29:101592.|Cell Rep. 2021 Sep 7;36 (10) :109659.|Cell Rep. 2024 Feb 27;43 (2) :113739.|Cell Signal. 2025 Jan 26:111627.|Clin Mol Hepatol. 2024 May 10.|Clin Transl Med. 2022 Sep;12 (9) :e1061.|Clin Transl Oncol. 2025 Jun;27 (6) :2557-2567.|Commun Biol. 2022 Dec 7;5 (1) :1340.|Engineering. 2024 Sep 6.|Eur J Med Res. 2025 Jan 17;30 (1) :35.|FASEB J. 2025 Mar 15;39 (5) :e70439.|Fish Shellfish Immunol. 2024 Aug 12:109829.|Food Chem Toxicol. 2022 Nov:169:113450.|Free Radic Biol Med. 2022 Sep:190:94-104.|Free Radical Bio Med. 2019 Sep:141:372-382.|Front Biosci (Landmark Ed) . 2024 Feb 6;29 (2) :66.|Front Immunol. 2022 Mar 10;13:771732.|Front Oncol. 2021 Apr 22:11:665763.|Front Oncol. 2021 Apr 6.|Front Pharmacol. 2022 May 16;13:848957.|Hepatology. 2022 Dec;76 (6) :1617-1633.|Infect Genet Evol. 2020 Nov;85:104552.|Int J Biol Sci. 2021 Oct 11;17 (15) :4207-4222.|Int J Biol Sci. 2022 Mar 14;18 (6) :2484-2496.|Int J Biol Sci. 2025 Jan 1;21 (2) :725-744.|J Agric Food Chem. 2024 Jun 12;72 (23) :13039-13053.|J Biol Chem. 2024 Jul 11:107549.|J Biomed Mater Res A. 2022 Aug;110 (8) :1448-1459.|J Cell Biol. 2022 Dec 5;221 (12) :e202207022.|J Cell Sci. 2022 Aug 1;135 (15) :jcs259090.|J Immunother Cancer. 2025 Oct 23;13 (10) :e012162.|J Invest Dermatol. 2023 Oct;143 (10) :1993-2006.e10.|J Orthop Surg Res. 2023 May 26;18 (1) :386.|Johns Hopkins University. 2025 Sep.|Med Oncol. 2025 Jul 14;42 (8) :332.|Mol Cell. 2024 Jun 21:S1097-2765 (24) 00477-5.|Mol Med. 2025 Oct 9;31 (1) :310.|Mol Metab. 2024 Jun:84:101953.|Nat Commun. 2021 Jun 16;12 (1) :3660.|Nat Commun. 2022 Jun 17;13 (1) :3486.|Nat Commun. 2024 Aug 3;15 (1) :6587.|Nat Commun. 2024 May 7;15 (1) :3805.|Nat Commun. 2025 Feb 1;16 (1) :1241.|Nat Commun. 2025 Jan 2;16 (1) :212.|Nat Commun. 2025 May 15;16 (1) :4502.|Nat Genet. 2025 Mar;57 (3) :680-693.|Nat Metab. 2022 Oct;4 (10) :1287-1305.|Nat Metab. 2025 Sep 30.|Neoplasia. 2025 Feb 3:61:101125.|Oncogene. 2025 Sep;44 (34) :3096-3112.|Oncol Rep. 2023 Jul;50 (1) :138.|Oncol Rep. 2023 Jul;50 (1) :141.|Oncotarget. 2016 Oct 11;7 (41) :67071-67086.|Pharmacol Res. 2021 Oct:172:105796.|PLoS Biol. 2025 Nov 24;23 (11) :e3003490.|Proc Natl Acad Sci U S A. 2021 Nov 16;118 (46) :e2105950118.|Redox Biol. 2018 Oct;19:412-428. |Redox Biol. 2021 Oct:46:102082.|Research (Wash D C) . 2023:6:0087.|Research Square Preprint. 2020 Sep.|Research Square Preprint. 2022 Feb.|Rheumatology (Oxford) . 2024 Jun 5:keae320.|Sci Adv. 2023 Apr 14;9 (15) :eadf8522.|Sci Adv. 2025 Aug 29;11 (35) :eadu6271.|Sci Immunol. 2023 Sep 29;8 (87) :eabq2424.|Sci Rep. 2024 Jan 18;14 (1) :1600.|Sci Rep. 2025 Aug 20;15 (1) :30552.|SSRN. 6 Dec 2022.|Stem Cell Res Ther. 2024 Sep 27;15 (1) :328.|Theranostics. 2020 May 16;10 (14) :6483-6499. |Universidade de São Paulo. Ribeirão Preto, 2021.|Vet Microbiol. 2024 Jan:288:109932.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
C2548-50X-ML650 100 µL
CD137 (4-1BB, TNFRSF9, 4-1BB ligand receptor, CD137, CD137 antigen, CDw137, ILA, T-cell antigen 4-1BB homolog, T-cell antigen ILA, Tumor necrosis factor receptor superfamily member 9 precursor) (BSA & Azide Free) (MaxLight 650) discontinued
Ask
View Details 
